After more than 25 years of research, a vaccine to prevent AIDS remains elusive. A new vaccine being developed at Mymetics is drawing attention because of its unique approach. The vaccine provides both first-line mucosal and second-line cellular immunity, according to the company. It is designed to block early transmission of the virus at mucosal surfaces, preventing it from spreading throughout the body.
Called MYMV101, the vaccine combines a peptide that stimulates mucosal immunity with a modified gp41 antigen for additional cellular immunity. The antigens are delivered via virosomes, which are lipid membranes modeled after envelope viruses. These lipid-based carriers contain functional fusion viral proteins and rationally designed antigens. Virosomes fuse with target cells, but they do not replicate. The virosome platform was created at Berna Biotech and improved by Virosome Biologics, which Mymetics acquired in 2009.
The route of administration of MYMV101 is unusual, too. The vaccine is first injected intramuscularly then followed by an intranasal booster dose. This approach induces IgA antibodies at mucosal surfaces to block viral entry, as well as IgG antibodies circulating in the blood. “Our vaccine represents a first line of defense before the virus can settle in the tissues and spread within the body. Targeting a virus before it enters the body is probably more efficacious than after it invades the body and infects it,” says Jacques-Francois Martin, CEO.